FindTrial
Sign In

Correlation of Tumor Infiltrating Lymphocytes and immune markers with pathological features in Oral Squamous Cell Carcinoma

Clinicopathological correlation of Tumor Infiltrating Lymphocytes and immune markers in Oral Squamous Cell Carcinoma - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/09/095486
Enrollment
40
Registered
2025-09-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

M.D.R.U, RUHS Collge of Medical Sciences, Jaipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Individuals with clinically and histopathologically diagnosed primary OSCC 2.Individuals who will undergo primary surgical treatment i.e composite resection surgery for oral squamous cell carcinoma at RUHS associated hospitals.

Exclusion criteria

Exclusion criteria: 1.Subjects with history of other cancers 2.Subjects with recurrent oral squamous cell carcinoma 3.Subjects diagnosed with any autoimmune disorder 4.Post treatment cases

Design outcomes

Primary

MeasureTime frame
Association between the density/expression of TILs and immune markers (CD73, PD-L1 and CTLA4) with clinicopathological parameters (tumor stage, grade, lymph node status, and other histopathological features) in OSCCTimepoint: end of the study—

Secondary

MeasureTime frame
association of clinicopathological features & immune markers in oral squamous cell carcinoma with sociodemographic charactersTimepoint: end of study—

Countries

India

Contacts

Public ContactDr Mudita Sharma

RUHS College of Medical Sciences

dr.muditadadhich@gmail.com07014772837

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026